ChemoCentryx, Inc. (CCXI)
(Delayed Data from NSDQ)
$12.93 USD
+0.14 (1.09%)
Updated May 3, 2019 04:00 PM ET
After-Market: $12.92 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[CCXI]
Reports for Purchase
Showing records 1 - 20 ( 84 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
2Q22 Results; Model Update; Acquisition of the Company Was Recently Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
Phase 1 Data for CCX559 to be Presented at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
1Q22 Results; Tavneos Launch Progressing Well; Tavneos Phase 3 Study in HS Could Start in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
PK/PD Data For CCX559 Presented at AACR Annual Meeting 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
4Q21 Results; Tavneos Sales Expected to Ramp Up Over 2022 in the U.S. and Europe
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E